PRESS RELEASE
Invitation to presentation of Nanoform's Q3 Report on
The company will hold a conference call and an online presentation on the same day at
The presentation will be broadcast live as a webcast available at: https://financialhearings.com/event/13383 (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Ffinancialhearings.com%2Fevent%2F13383&data=04%7C01%7C%7C8a5c8dd32daf4019b18c08d8871632b6%7C70e2685be6cc4120935cc2b4e1d1915b%7C0%7C0%7C637407876708354730%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=nChexXsqwlZs4%2FVoIYOlbOyPAc1vnTa1ENf7RqX5Eo0%3D&reserved=0)
Teleconference dial-in numbers:
For further information, please contact:
hvh@nanoform.com / +46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nanoforming services. The Company's patented and scalable Controlled Expansion of Supercritical Solutions (CESS[®)] technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform's unique technology provides novel opportunities in many value-enhancing drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/invitation-to-presentation-of-nanoform-s-q3-report-on-november-27,c3237388
https://mb.cision.com/Main/18905/3237388/1335279.pdf
(c) 2020 Cision. All rights reserved., source